Evidence map›Paper›PMID 31551371›Full record

SynthesisBMJ open2019

Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis.

Oghenowede Eyawo, Gwenyth Brockman, Charles H Goldsmith, Mark W Hull, Scott A Lear, Matthew Bennett, Silvia Guillemi, Conrado Franco-Villalobos, Ahmed Adam, Edward J Mills and 2 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 4 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Article
  11. Hidden risks of first-line regimen switching in antiretroviral therapy-treated patients.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2025
    Article
  12. Statin use in people with HIV.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Article
  13. Review
  14. Review
  15. Burden of Chronic Health Conditions Among People With HIV and Common Non-AIDS-Defining Cancers.Journal of the National Comprehensive Cancer Network : JNCCN · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Oghenowede EyawoFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada oeyawo@yorku.ca.ORCID 0000-0001-6263-1076
Gwenyth BrockmanGeorge & Fay Yee Centre for Healthcare Innovation, University of Manitoba, Winnipeg, Manitoba, Canada.
Charles H GoldsmithFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Mark W HullBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Scott A LearFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Matthew BennettDivision of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Silvia GuillemiBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Conrado Franco-VillalobosSchool of Public Health, University of Alberta, Edmonton, Alberta, Canada.
Ahmed AdamFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Edward J MillsDepartment of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0003-3120-9694
Julio S G MontanerBritish Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Robert S HoggFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Simon Fraser University · CAUniversity of British Columbia · CAAIDS Vancouver · CAGeorge & Fay Yee Centre for Healthcare Innovation · CAMcMaster University · CAProvidence Health Care · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCardiovascular disease (CVD) is one of the leading non-AIDS-defining causes of death among HIV-positive (HIV+) individuals. However, the evidence surrounding specific components of CVD risk remains inconclusive. We conducted a systematic review and meta-analysis to synthesise the available evidence and establish the risk of myocardial infarction (MI) among HIV+ compared with uninfected individuals. We also examined MI risk within subgroups of HIV+ individuals according to exposure to combination antiretroviral therapy (ART), ART class/regimen, CD4 cell count and plasma viral load (pVL) levels.

designSystematic review and meta-analysis. DATA SOURCES: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews until 18 July 2018. Furthermore, we scanned recent HIV conference abstracts (CROI, IAS/AIDS) and bibliographies of relevant articles. ELIGIBILITY CRITERIA: Original studies published after December 1999 and reporting comparative data relating to the rate of MI among HIV+ individuals were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers working in duplicate, independently extracted data. Data were pooled using random-effects meta-analysis and reported as relative risk (RR) with 95% CI.

resultsThirty-two of the 8130 identified records were included in the review. The pooled RR suggests that HIV+ individuals have a greater risk of MI compared with uninfected individuals (RR: 1.73; 95% CI 1.44 to 2.08). Depending on risk stratification, there was moderate variation according to ART uptake (RR, ART-treated=1.80; 95% CI 1.17 to 2.77; ART-untreated HIV+ individuals: 1.25; 95% CI 0.93 to 1.67, both relative to uninfected individuals). We found low CD4 count, high pVL and certain ART characteristics including cumulative ART exposure, any/cumulative use of protease inhibitors as a class, and exposure to specific ART drugs (eg, abacavir) to be importantly associated with a greater MI risk.

conclusionsOur results indicate that HIV infection, low CD4, high pVL, cumulative ART use in general including certain exposure to specific ART class/regimen are associated with increased risk of MI. The association with cumulative ART may be an index of the duration of HIV infection with its attendant inflammation, and not entirely the effect of cumulative exposure to ART per se. PROSPERO REGISTRATION NUMBER: CRD42014012977.

Indexed as

Anti-HIV AgentsCD4 Lymphocyte CountHIV InfectionsHumansMyocardial InfarctionRiskViral LoadAnti-HIV AgentsCardiovascular diseaseCombination antiretroviral therapy (ART)HIVMeta-analysisMyocardial infarctionRelative riskSystematic review

Identifiers

PMID31551371
PMCPMC6773316
OpenAlexW2976807690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.